BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

459 related articles for article (PubMed ID: 12168889)

  • 1. A dose-escalation study of irinotecan (CPT-11) in combination with gemcitabine in patients with advanced non-small cell lung cancer previously treated with a cisplatin-based front line chemotherapy.
    Kakolyris SS; Kouroussis C; Koukourakis M; Kalbakis K; Mavroudis D; Vardakis N; Georgoulias V
    Anticancer Res; 2002; 22(3):1891-6. PubMed ID: 12168889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A dose-escalation study of irinotecan (CPT-11) in combination with cisplatin in patients with advanced non-small cell lung cancer previously treated with a docetaxel-based front line chemotherapy.
    Kakolyris S; Souglakos J; Agelaki S; Kourousis CH; Mavroudis D; Sarra E; Malliotakis P; Georgoulias V
    Lung Cancer; 2000 Dec; 30(3):193-8. PubMed ID: 11137204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A phase I study of gemcitabine and irinotecan as second line treatment for advanced non-small cell lung cancer].
    Ryo H; Toyama K; Isobe K; Sugino K; Sano G; Yamada H; Hiroi M; Hojyo T; Kimura K
    Gan To Kagaku Ryoho; 2003 Feb; 30(2):237-42. PubMed ID: 12610872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Irinotecan and gemcitabine in patients with advanced non-small cell lung cancer, previously treated with cisplatin-based chemotherapy. A phase II study.
    Pectasides D; Mylonakis N; Farmakis D; Nikolaou M; Koumpou M; Katselis I; Gaglia A; Kostopoulou V; Karabelis A; Kosmas C
    Anticancer Res; 2003; 23(5b):4205-11. PubMed ID: 14666626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I-II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens.
    Kosmas C; Tsavaris N; Syrigos K; Koutras A; Tsakonas G; Makatsoris T; Mylonakis N; Karabelis A; Stathopoulos GP; Kalofonos HP
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):51-9. PubMed ID: 16622691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of combination chemotherapy with gemcitabine and irinotecan for non-small cell lung cancer.
    Nishio M; Ohyanagi F; Taguch F; Matsuda M; Sato Y; Okumura S; Nakagawa K; Horai T
    Lung Cancer; 2005 Apr; 48(1):115-9. PubMed ID: 15777978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salvage treatment of advanced non-small-cell lung cancer previously treated with docetaxel-based front-line chemotherapy with irinotecan (CPT-11) in combination with cisplatin.
    Kakolyris S; Kouroussis C; Kalbakis K; Mavroudis D; Souglakos J; Nvardakis ; Kremos S; Georgoulias V
    Ann Oncol; 2000 Jun; 11(6):757-60. PubMed ID: 10942068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study.
    Georgoulias V; Kouroussis C; Agelidou A; Boukovinas I; Palamidas P; Stavrinidis E; Polyzos A; Syrigos K; Veslemes M; Toubis M; Ardavanis A; Tselepatiotis E; Vlachonikolis I;
    Br J Cancer; 2004 Aug; 91(3):482-8. PubMed ID: 15238986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cisplatin and irinotecan (CPT-11) as second-line treatment in patients with advanced non-small cell lung cancer.
    Kakolyris S; Kouroussis C; Souglakos J; Agelaki S; Kalbakis K; Vardakis N; Vamvakas L; Georgoulias V
    Lung Cancer; 2001 Dec; 34 Suppl 4():S71-6. PubMed ID: 11742707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I clinical trial of irinotecan (CPT-11), 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, and cisplatin in combination with fixed dose of vindesine in advanced non-small cell lung cancer.
    Shinkai T; Arioka H; Kunikane H; Eguchi K; Sasaki Y; Tamura T; Ohe Y; Oshita F; Nishio M; Karato A
    Cancer Res; 1994 May; 54(10):2636-42. PubMed ID: 8168091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study with dose escalation of gemcitabine and cisplatin in combination with ifosfamide (GIP) in patients with non-small-cell lung carcinoma.
    Bourgeois H; Billiart I; Chabrun V; Chieze S; Lemerre D; Germain T; Ferrand V; Meurice JC; Daban A; Tourani JM
    Am J Clin Oncol; 2004 Feb; 27(1):89-95. PubMed ID: 14758140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cisplatin, gemcitabine, and paclitaxel in locally advanced or metastatic non-small-cell lung cancer: a phase I-II study. Southern Italy Cooperative Oncology Group.
    Frasci G; Panza N; Comella P; Nicolella GP; Natale M; Manzione L; Bilancia D; Cioffi R; Maiorino L; De Cataldis G; Belli M; Micillo E; Mascia V; Massidda B; Lorusso V; De Lena M; Carpagnano F; Contu A; Pusceddu G; Comella G
    J Clin Oncol; 1999 Aug; 17(8):2316-25. PubMed ID: 10561293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I dose-finding study of biweekly irinotecan in combination with fixed doses of 5-fluorouracil/leucovorin, gemcitabine and cisplatin (G-FLIP) in patients with advanced pancreatic cancer or other solid tumors.
    Rachamalla R; Malamud S; Grossbard ML; Mathew S; Dietrich M; Kozuch P
    Anticancer Drugs; 2004 Mar; 15(3):211-7. PubMed ID: 15014353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I/II study of escalating doses of nedaplatin in combination with irinotecan for advanced non-small-cell lung cancer.
    Oshita F; Yamada K; Kato Y; Ikehara M; Noda K; Tanaka G; Nomura I; Suzuki R; Saito H
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):73-8. PubMed ID: 12750839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of combination chemotherapy with gemcitabine and irinotecan in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens.
    Ohyanagi F; Taguchi F; Horai T; Kasahara K; Takeda Y; Shibata K; Shirosaki H; Nishio M
    Jpn J Clin Oncol; 2006 Sep; 36(9):547-51. PubMed ID: 16870693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer.
    Masuda N; Fukuoka M; Kudoh S; Matsui K; Kusunoki Y; Takada M; Nakagawa K; Hirashima T; Tsukada H; Yana T
    J Clin Oncol; 1994 Sep; 12(9):1833-41. PubMed ID: 7521905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Weekly irinotecan and cisplatin in advanced non-small cell lung cancer: a multicenter phase II study.
    Jagasia MH; Langer CJ; Johnson DH; Yunus F; Rodgers JS; Schlabach LL; Cohen AG; Shyr Y; Carbone DP; Devore RF
    Clin Cancer Res; 2001 Jan; 7(1):68-73. PubMed ID: 11205920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I/II study of gemcitabine and vinorelbine plus cisplatin in non-small cell lung cancer.
    Esteban E; Fra J; Sala M; Carrasco J; Corral N; Vieitez JM; Estrada E; Palacio I; Buesa JM; Lacave AJ
    Invest New Drugs; 2002 Aug; 20(3):317-26. PubMed ID: 12201494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel combination of cisplatin, irinotecan, and capecitabine in patients with advanced cancer.
    Jefford M; Michael M; Rosenthal MA; Davis ID; Green M; McClure B; Smith J; Waite B; Zalcberg J
    Invest New Drugs; 2004 Apr; 22(2):185-92. PubMed ID: 14739668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II study.
    Kakolyris S; Papadakis E; Tsiafaki X; Kalofonos C; Rapti A; Toubis M; Bania E; Kouroussis C; Chainis K; Androulakis N; Agelaki S; Sarra E; Vardakis N; Georgoulias V;
    Lung Cancer; 2001 May; 32(2):179-87. PubMed ID: 11325489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.